A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs KY-1005 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kymab
- 27 Nov 2019 Planned End Date changed from 1 Jun 2020 to 1 Sep 2020.
- 27 Nov 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Apr 2020.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.